GlucoTrack's subsidiary, Lōkahi Therapeutics, is progressing its LT-100 development to a single subcutaneous injection, a significant simplification from 15 intradermal injections. This move, supported by a successful FDA Type C meeting and nonclinical study, aims to improve patient convenience and potentially accelerate clinical trials, with initial readouts expected in H1 2027.
Lōkahi Therapeutics, a subsidiary of GlucoTrack (GCTK), announced progress in simplifying the administration of its drug candidate, LT-100, from 15 intradermal injections to a single subcutaneous injection. This development follows a positive FDA Type C meeting and a successful nonclinical study, providing confidence to move into clinical evaluation of the simplified approach as early as Q4 2026, with initial results in H1 2027. This is a significant positive for GCTK as it addresses a major patient convenience and adherence factor, potentially broadening the market appeal and accelerating the development timeline for LT-100. For traders, this represents a long-term opportunity if the simplified administration proves successful in clinical trials, as it could significantly de-risk the product's commercial viability. The short-term impact might be moderate as clinical trials are still in the future, but it signals positive momentum.